EM1705H "Crossing the Intersection of Genetics and Inflammation to Find a Cure for Pulmonary Arterial Hypertension" (IM GR-050517)
The Grand Rounds will be an update on why current treatments for pulmonary arterial hypertension were not curing the disease and how basic research can lead to new disease modifying therapies.
UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.
At the conclusion of this activity, the participant should be able to:
- Provide an overview of pulmonary arterial hypertension including predisposing conditions, genetics, and current treatments and outcome.
- Provide evidence that chronic inflammation and altered immunity are important in the pathological process of pulmonary hypertension.
- Explain why restoring the downstream function of BMPR2 a fruitful avenue to pursue as a disease modifying therapy.
- Show how induced pluripotent cells be used to model disease and to develop personalized therapies for pulmonary arterial hypertension.
Marlene Rabinovitch, M.D.
Dwight and Vera Dunlevie Professor in Pediatric Cardiology
Staff Scientist, Vera Moulton Wall Center for Pulmonary Vascular Disease
Stanford Univeristy School of Medicine
Robert L. Johnson, Jr., M.D. Lectureship in Internal Medicine
- 1.00 AMA
Activities should be run with recent versions of common browsers, including Internet Explorer, Firefox and Google Chrome